Looking for retatrutide for laboratory research? See it at OXpeptides (research use only)
Retatrutide Peptide
Retatrutide Reddit

Retatrutide on Reddit: seven things people get wrong, checked against the trials

Reddit is where most people first read about retatrutide, and it is where most of the errors about it start. This article takes the seven claims that come up most often in those threads and checks each against the published trials, without quoting or naming any user.

Published 21 September 2026Updated 21 September 20269 min readSources checked 21 September 2026

Key facts

  • Trial participants reached 12 mg only after months of stepwise escalation from a low starting dose; the phase 2 trial found fewer gastrointestinal events with a lower starting dose.
  • Weight loss in trials was gradual: −17.5% at 24 weeks and −24.2% at 48 weeks on 12 mg in phase 2, and it had not plateaued at 80 weeks in TRIUMPH-1 (−28.3%).
  • Retatrutide is not approved anywhere and no product sold online is pharmaceutical retatrutide; Lilly plans an FDA filing in Q1 2027.
  • A certificate of analysis proves what was in one tested sample, not what is in the container you receive; it is necessary, not sufficient.
A laptop with a blank white screen on a wooden table beside a cup of black coffee and a notebook in daylight.

Photograph: editorial illustration for this article. It does not show retatrutide.

On this page
Why Reddit gets it wrong1. Dosing2. Speed3. Side effects4. Approval5. What a COA proves6. Comparison with tirzepatide7. StoppingHow to use Reddit wellFAQSources

Why does Reddit get retatrutide wrong so often?

Because it works the way Reddit works. A thread starts with a trial headline, someone adds what a vendor told them, someone else adds what happened to them in week three, and by the hundredth comment the three kinds of information have merged. Nobody is lying; the medium just strips the labels off. The subreddits that discuss retatrutide are among the largest peptide communities online, and searches for the phrase retatrutide reddit run to 12,100 a month in the United States according to Google Ads data we pulled in September 2026. Below are the claims that recur most, each checked against the published record. No user is quoted or named.

1. "The dose is 2 mg a week to start"

Trial protocols started lower and climbed slowly. The phase 2 obesity trial began participants on 1, 2 or 4 mg and stepped up in stages toward their assigned target of 1, 4, 8 or 12 mg, and the paper reports that a lower starting dose produced fewer gastrointestinal adverse events[1]. Phase 3 used targets of 4, 9 and 12 mg reached over months[6]. Threads that quote a single "starting dose" as if it were a fixed fact are collapsing a months-long schedule into one number. They are also quoting a protocol for an unapproved drug as if it were a dosing instruction, which it is not.

2. "You lose 20 pounds in the first month"

The trial curves are slow and steady. On 12 mg in phase 2, mean weight change was −17.5% at 24 weeks and −24.2% at 48 weeks[1]. In TRIUMPH-1 the 12 mg arm reached −28.3% at 80 weeks and, in the extension for people with a BMI of 35 or more, −30.3% at 104 weeks[2]. Early weeks on a low escalation dose produce modest change; the large numbers come from more than a year on the full dose.

Phase 2 obesity trial: weight change over 48 weeks by dosePlacebo −1.6% at 24 weeks and −2.1% at 48; 4 mg −12.9% and −17.1%; 8 mg −17.3% and −22.8%; 12 mg −17.5% and −24.2%.0%-5%-10%-15%-20%-25%wk 0wk 24wk 48Placebo -2.1%4 mg -17.1%8 mg -22.8%12 mg -24.2%
Mean percent change in body weight over 48 weeks in the phase 2 obesity trial, by dose. The curve is gradual and dose-dependent. Source: Jastreboff et al., NEJM 2023.

3. "The side effects are mild, just some nausea"

Nausea is the most common effect, but "mild" is a summary of the median, not of everyone. In TRIUMPH-1, nausea affected 42.4% of the 12 mg group, diarrhoea 32.0% and constipation 26.1%, and 11.3% of that group stopped the drug because of adverse events, against 4.9% on placebo[2]. Phase 2 also documented a dose-related rise in heart rate that peaked around week 24[1], something threads rarely mention. The full record is in GLP-3 side effects.

4. "It just got approved"

It did not. Positive phase 3 results were announced on 11 December 2025, 21 May 2026 and 23 July 2026. In the July announcement Lilly said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027[4]. A filing is not an approval, and a plan to file is not a filing. The details are in retatrutide FDA approval.

5. "This vendor has a COA, so it's legit"

A certificate of analysis says what a laboratory found in the sample it was sent. It does not say that the container in your hand came from the same batch, that the batch was stored properly, or that the vendor did not photograph one good certificate and reuse it. A COA with a named laboratory, a lot number, a mass spectrometry identity check and an HPLC purity figure is the minimum; anything less is decoration. We walk through the sections in how to read a retatrutide COA.

6. "It's basically tirzepatide but stronger"

Half right. Both are weekly Lilly peptides built on a GIP backbone, and in separate pivotal trials the top retatrutide dose produced more mean weight loss (−28.3% at 80 weeks) than the top tirzepatide dose (−20.9% at 72 weeks)[2][3]. But retatrutide has a third receptor, glucagon, which changes the side-effect profile, adds the heart-rate effect and strips fat from the liver in a way tirzepatide does not. "Stronger" hides a different mechanism. See retatrutide vs Mounjaro.

7. "You can stop and keep the weight off"

No published retatrutide data say that. The phase 2 trials ended at 48 weeks (obesity) and 36 weeks (diabetes) with no off-drug follow-up in the primary papers[1][5], and the phase 3 program includes maintenance studies whose results Lilly has not yet announced[4]. Every approved drug in this class shows weight regain after discontinuation in its own trials. Until retatrutide's maintenance data are published, claims about what happens after stopping are guesses.

How to use Reddit well on this topic

Reading Reddit threads about retatrutide
When a post saysAsk
A doseIs this a trial protocol, a vendor suggestion or one person's habit?
A weight numberOver how many weeks, from what starting weight, on what dose?
A side effectDuring escalation or at steady dose, and how many people in the trials had it?
A COAWhich lab, which lot, does it include mass spec and HPLC, and is the vendor named on it?
Approval newsIs there an FDA action, or a company press release about a plan?
This article checks claims against published trials. It does not quote, name or evaluate any individual. Retatrutide is investigational, not approved by the FDA or the EMA, and nothing here is a recommendation to use it.

Frequently asked questions

Is Reddit a reliable source on retatrutide?

It is a fast source, not a reliable one. Threads mix trial data, vendor marketing and personal anecdote without labels. Every factual claim can be checked against the NEJM and Lancet publications and the ClinicalTrials.gov records, which is what this article does.

What dose of retatrutide do trials use?

Phase 2 tested 1, 4, 8 and 12 mg weekly, reached by gradual escalation; phase 3 used 4, 9 and 12 mg. These are protocol doses for an investigational drug, not recommendations.

How fast does retatrutide work in trials?

Mean weight change on 12 mg was −17.5% at 24 weeks and −24.2% at 48 weeks in phase 2, and −28.3% at 80 weeks in TRIUMPH-1. It is a curve over more than a year, not a few weeks.

Why do Reddit posts say retatrutide is FDA approved?

Because positive phase 3 news gets summarised as approval. It is not. Lilly plans to file with the FDA in the first quarter of 2027; a decision would follow months later.

Sources

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. DOI 10.1056/NEJMoa2301972
  2. Eli Lilly and Company, press release, 21 May 2026. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. DOI 10.1056/NEJMoa2206038
  4. Eli Lilly and Company, press release, 23 July 2026. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3 topline results). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  5. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. DOI 10.1016/S0140-6736(23)01053-X
  6. ClinicalTrials.gov. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1). Phase 3, 2,335 participants, started 10 July 2023, primary completion 6 April 2026, status Completed. NCT05929066

DOIs were checked against the CrossRef API and trial identifiers against the ClinicalTrials.gov API v2 on 2026-09-21. Press releases are cited by URL because topline results are not yet in a peer-reviewed journal.